Physician

Mark Lazarovich, MD

According to 2025 Medicare claims, Mark Lazarovich, MD (NPI: 1083619431) practices allergy/immunology in the Burlington-South Burlington, VT market, with the plurality of this provider's patient population coming from Chittenden, VT. This provider's primary affiliated billing organization is TIMBER LANE ALLERGY & ASTHMA ASSOCIATES, PC (NPI: 1457356818; TIN: 030349701) and primary practice location at 05403-5201.

Lazarovich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 467 traditional Medicare patients, billed 9,370 HCPCS/CPT codes, and received $110,220 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,659 prescription claims across 285 beneficiaries totaling $1,108,122 in drug costs, led by Fasenra Pen (Benralizumab). DME data shows 43 claims. Open Payments data shows 1 records totaling $84. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $187,717 to $110,220. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $326,678 to $1,108,122. For DME billing, this smaller-volume category moved sharply higher in recent years, from $508 to $2,162.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$115K$230K2015 Medicare payment: $187,717 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $230,077 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $214,995 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $178,873 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $161,708 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $79,751 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $94,956 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $69,716 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $100,261 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $110,220 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
201539311,434$187,717
201643713,213$230,077
201744512,631$214,995
201845310,539$178,873
201947710,720$161,708
20203455,642$79,751
20214286,659$94,956
20223425,012$69,716
20234248,372$100,261
20244679,370$110,220

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$554K$1.1M2015 Drug cost: $326,678 (USD; Tot_Drug_Cst)2016 Drug cost: $364,418 (USD; Tot_Drug_Cst)2017 Drug cost: $446,171 (USD; Tot_Drug_Cst)2018 Drug cost: $421,682 (USD; Tot_Drug_Cst)2019 Drug cost: $585,934 (USD; Tot_Drug_Cst)2020 Drug cost: $867,958 (USD; Tot_Drug_Cst)2021 Drug cost: $787,977 (USD; Tot_Drug_Cst)2022 Drug cost: $759,885 (USD; Tot_Drug_Cst)2023 Drug cost: $1,016,705 (USD; Tot_Drug_Cst)2024 Drug cost: $1,108,122 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20152311,448$326,678
20162331,502$364,418
20172361,538$446,171
20182401,547$421,682
20192531,622$585,934
20202241,559$867,958
20212351,483$787,977
20222411,452$759,885
20232661,543$1,016,705
20242851,659$1,108,122

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

DME Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: DME_Suplr_Mdcr_Pymt_Amt. Source: Medicare DME, Devices & Supplies by Referring Provider.0$65K$129K2015 Medicare payment: $256 (USD; DME_Suplr_Mdcr_Pymt_Amt)2018 Medicare payment: $97,304 (USD; DME_Suplr_Mdcr_Pymt_Amt)2019 Medicare payment: $101,050 (USD; DME_Suplr_Mdcr_Pymt_Amt)2020 Medicare payment: $98,181 (USD; DME_Suplr_Mdcr_Pymt_Amt)2021 Medicare payment: $122,114 (USD; DME_Suplr_Mdcr_Pymt_Amt)2022 Medicare payment: $120,087 (USD; DME_Suplr_Mdcr_Pymt_Amt)2023 Medicare payment: $116,030 (USD; DME_Suplr_Mdcr_Pymt_Amt)2024 Medicare payment: $129,176 (USD; DME_Suplr_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClaimsPayment
2015N/R25$256
2016N/RN/RN/R
2017N/RN/RN/R
2018N/R51$97,304
2019N/R39$101,050
2020N/R35$98,181
2021N/R42$122,114
2022N/R39$120,087
2023N/R42$116,030
2024N/R43$129,176

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more184263$81
94726Test to determine lung volumes using sensors207294$38
94010Test to measure expiratory airflow and volume177250$18
95012Test to measure the level of nitric oxide gas147179$14
95004Test for allergy using allergenic extract1636,156$2

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Fasenra PenBenralizumab442,282$257,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter2007,800$162,264
Dupixent PenDupilumab31924$123,920
Breztri AerosphereBudesonide/Glycopyr/Formoterol1475,312$101,426
Dupixent SyringeDupilumab24672$85,945

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS CodeHCPCS DescriptionSupplier Rental IndicatorTotal Supplier BeneficiariesTotal Supplier ClaimsTotal Medicare Payment Amount
J1559Injection, immune globulin (hizentra), 100 mgNN/R13$127,537
A4221Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)NN/R17$1,269
K0552Supplies for external non-insulin drug infusion pump, syringe type cartridge, sterile, eachNN/R13$370

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.1$84AstraZeneca Pharmaceuticals LP
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Mark Lazarovich, MD?

Tedicare shows public-source Medicare data for Mark Lazarovich, MD (NPI 1083619431), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Lazarovich, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark Lazarovich, MD?

Mark Lazarovich, MD is linked to TIMBER LANE ALLERGY & ASTHMA ASSOCIATES, PC (billing NPI 1457356818) in the available physician profile data.

Does Mark Lazarovich, MD have Open Payments data?

Mark Lazarovich, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.